Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation

NCT07561554 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors (Phase 1)

Interventions

DRUG: HSK42360-Na

Sponsor

Haisco Pharmaceutical Group Co., Ltd.